Clinical Trials Logo

Clinical Trial Summary

Assess impact of ILE and NAC in morbidity and mortality when used as adjuvant therapy to routine management of acute ALP poisoning.


Clinical Trial Description

Aluminum phosphide (ALP) is one of the solid fumigant pesticides. In Egypt, ALP is extensively used to protect grains against insects and rodents. It is available in the form of tablets known as "grain tablet". Suicidal ingestion of ALP tablets is obviously increasing in developing countries. This is attributed to its wide use, free availability in the market, and its low cost. Aluminum phosphide toxicity is extremely fatal. The conveyed mortality rate differs from 37-100%. More than 90% of patients die within the first 24 hours, mainly due to cardiac dysrhythmia. Despite continuous research, no effective antidote has been reported for this lethal poisoning so far. PH3 is phosphorus trihydride and solubility of phosphorus can affect PH3. Solubilities of phosphorus are as follows: In water: 1 part/300,000 parts water; in absolute alcohol: 1 g/400 mL. One gram phosphorus dissolves in 80 ml olive oil, 60 ml oil of turpentine, and about 100 mL of almond oil. So, PH3 might also have lipid soluble property and used IV lipid emulsion may counter its effects. Intravenous lipid emulsion (ILE) is a sterile fat emulsion prepared for intravenous administration as a source of calories and essential fatty acids. Its main components include up to 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection. In addition, sodium hydroxide has been added to adjust the pH, so that the final pH is 8. Based on animal models and clinical studies, ILE is an established antidote for local-anesthetic drugs systemic toxicity. Besides, ILE has been well used for resuscitation of severe toxicities caused by various lipophilic non-local anesthetic drugs. N-acetylcysteine (NAC) is a well-studied compound which is commonly used in the treatment of paracetamol poisoning. It has shown to replenish cellular glutathione stores in addition to the strong antioxidant properties. NAC has shown to reduce mortality, hospitalization time, and need for mechanical ventilation in ALP poisoning. A cohort study by Agarwal reported survival benefit in patients who received treatment with NAC compared to the control group. Brain natriuretic peptide (BNP) is an excellent biomarker because it can be detected in the early stages of ischemia and decreases shortly after ischemia allowing better detection of re-injury. A metabolite of BNP, Nterminal pro-BNP, NT-proBNP, is relatively easy to measure and predicts short and long term outcomes. BNP is a 32-amino-acid peptide synthesized predominantly from the ventricular myocardium and is released in proportion to the degree of wall stress. Although it has gained recent prominence in the diagnosis and treatment of heart failure, BNP has recently shown promise in predicting the extent of myocardial ischemia in acute coronary syndromes. For instance, the magnitude of BNP released between 1 and 7 days after a myocardial infarction is predictive of left ventricular dysfunction, heart failure, and mortality. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05370729
Study type Interventional
Source Assiut University
Contact Tassbeeh Kamal
Phone 01065656202
Email tk.zanaty_92@med.aun.edu.eg
Status Not yet recruiting
Phase N/A
Start date May 2022
Completion date May 2025

See also
  Status Clinical Trial Phase
Terminated NCT03940651 - Cardiac and Renal Biomarkers in Arthroplasty Surgery Phase 4
Completed NCT01688648 - Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft N/A
Completed NCT04794062 - Myocardial Injury and Quality of Life After COVID-19
Recruiting NCT04750616 - NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial Phase 2
Recruiting NCT04615871 - Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19 Phase 2
Completed NCT05691764 - Effect of Cyclosporine and Remote Ischemic Preconditioning in Reperfusion Ischemia Injury on Tetralogy Fallot Patients With Correction Surgery N/A
Withdrawn NCT04139655 - Colchicine Prevents Myocardial Injury After Non-Cardiac Surgery Pilot Study N/A
Completed NCT04436016 - PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery Phase 4
Recruiting NCT05748691 - Switching From Cardiac Troponin I to T
Completed NCT03338504 - Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction
Recruiting NCT03013634 - Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation N/A
Completed NCT00007358 - Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus N/A
Recruiting NCT05714618 - MR Evidence of Cardiac Inflammation Post-Stroke
Recruiting NCT04624503 - Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19
Active, not recruiting NCT03339180 - Cardiac Injury in Patients With Influenza
Completed NCT03010839 - Cardiopulmonary Protective Effects of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery N/A
Recruiting NCT04743765 - HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial N/A
Enrolling by invitation NCT03253835 - Cardiac Blood Flow Patterns Associated With Left Ventricular Myocardial Damage
Completed NCT00817791 - Preconditioning With Hyperbaric Oxygen in Cardiovascular Surgery N/A
Completed NCT04149314 - The "Hypotension Prediction Index" in Patients Undergoing Lung Surgery N/A